Literature DB >> 18540480

Photosensitizing properties of Actarit, an antirheumatic drug.

Nieves Canudas1, Lillian Figueroa, Delimar Zamora, José E Villamizar, Arlen Guedez, Juan M Fuentes, Cristina Castelli, Antonieta Taddei.   

Abstract

The photobiological properties of 4-acetylaminophenylacetic acid (Actarit, ACT, MS-932, CAS 18699-02-0) were studied using in vitro phototoxicity assays: photohemolysis, photoperoxidation of linoleic acid and Candida sp phototoxicity test. ACT reduced nitro blue tetrazolium (NBT) when irradiated with lambda > or = 300 nm in deoxygenated aqueous buffer solution (pH 7.4). The photohemolysis rate and photoperoxidation of linoleic acid were inhibited significantly by reduced glutathione. ACT was phototoxic to Candida sp. The isolation and identification of the photodegradation products of ACT in phosphate buffered saline solution (pH 7.4) and methanol were studied under aerobic conditions. Four compounds were identified and two of them isolated and characterized by spectroscopic methods. A photodecarboxylation with the participation of oxygen via a type I mechanism was proposed for the photodegradation of ACT which undergoes direct electron transfer from the excited state of ACT carboxylate and homolytic rupture of the alpha-carbon bond. A photodynamic mechanism involving radicals and electron transfer reactions was suggested for the observed in vitro phototoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18540480     DOI: 10.1055/s-0031-1296490

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Stability-indicating assay method for determination of actarit, its process related impurities and degradation products: Insight into stability profile and degradation pathways.

Authors:  A Abiramasundari; Rahul P Joshi; Hitesh B Jalani; Jayesh A Sharma; Dhaivat H Pandya; Amit N Pandya; Vasudevan Sudarsanam; Kamala K Vasu
Journal:  J Pharm Anal       Date:  2014-01-25

2.  Identification and Validation of Carbonic Anhydrase II as the First Target of the Anti-Inflammatory Drug Actarit.

Authors:  Ghita Ghislat; Taufiq Rahman; Pedro J Ballester
Journal:  Biomolecules       Date:  2020-11-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.